OCUL
Income statement / Annual
Last year (2024), Ocular Therapeutix, Inc.'s total revenue was $63.72 M,
an increase of 9.03% from the previous year.
In 2024, Ocular Therapeutix, Inc.'s net income was -$193.51 M.
See Ocular Therapeutix, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$63.72 M |
$58.44 M |
$51.49 M |
$43.52 M |
$17.40 M |
$4.23 M |
$1.99 M |
$1.92 M |
$1.89 M |
$1.75 M |
| Cost of Revenue |
$5.63 M
|
$5.28 M
|
$4.54 M
|
$4.41 M
|
$2.08 M
|
$2.33 M
|
$465,000.00
|
$457,000.00
|
$443,000.00
|
$319,000.00
|
| Gross Profit |
$58.10 M
|
$53.16 M
|
$46.95 M
|
$39.12 M
|
$15.32 M
|
$1.90 M
|
$1.53 M
|
$1.47 M
|
$1.44 M
|
$1.43 M
|
| Gross Profit Ratio |
0.91
|
0.91
|
0.91
|
0.9
|
0.88
|
0.45
|
0.77
|
0.76
|
0.77
|
0.82
|
| Research and Development Expenses |
$127.64 M
|
$61.06 M
|
$53.46 M
|
$50.08 M
|
$28.69 M
|
$41.09 M
|
$36.92 M
|
$30.88 M
|
$27.07 M
|
$26.61 M
|
| General & Administrative Expenses |
$60.65 M
|
$33.94 M
|
$32.22 M
|
$31.88 M
|
$22.86 M
|
$22.12 M
|
$18.79 M
|
$15.51 M
|
$11.00 M
|
$9.17 M
|
| Selling & Marketing Expenses |
$41.59 M
|
$40.55 M
|
$39.92 M
|
$35.19 M
|
$26.61 M
|
$24.49 M
|
$4.94 M
|
$17.00 M
|
$6.70 M
|
$3.85 M
|
| Selling, General & Administrative Expenses |
$102.24 M
|
$74.49 M
|
$72.15 M
|
$67.07 M
|
$49.47 M
|
$46.61 M
|
$23.73 M
|
$32.51 M
|
$17.71 M
|
$13.02 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$1,000.00
|
$1,000.00
|
$0.00
|
-$8,000.00
|
$0.00
|
$5,000.00
|
-$1,000.00
|
$7,000.00
|
| Operating Expenses |
$229.88 M
|
$135.54 M
|
$125.61 M
|
$117.15 M
|
$78.17 M
|
$87.70 M
|
$60.64 M
|
$63.39 M
|
$44.77 M
|
$39.63 M
|
| Cost And Expenses |
$235.50 M
|
$140.83 M
|
$130.15 M
|
$121.56 M
|
$80.25 M
|
$90.03 M
|
$61.11 M
|
$63.85 M
|
$45.21 M
|
$39.95 M
|
| Interest Income |
$20.28 M
|
$3.98 M
|
$798,000.00
|
$33,000.00
|
$168,000.00
|
$1.23 M
|
$879,000.00
|
$424,000.00
|
$304,000.00
|
$166,000.00
|
| Interest Expense |
$13.58 M
|
$11.34 M
|
$7.02 M
|
$6.67 M
|
$6.77 M
|
$6.10 M
|
$1.74 M
|
$1.89 M
|
$1.68 M
|
$1.72 M
|
| Depreciation & Amortization |
$3.79 M
|
$2.98 M
|
$2.11 M
|
$2.42 M
|
$2.77 M
|
$2.53 M
|
$2.29 M
|
$1.63 M
|
$881,000.00
|
$754,000.00
|
| EBITDA |
-$176.14 M |
-$66.42 M |
-$61.91 M |
-$75.62 M |
-$146.10 M |
-$77.74 M |
-$55.95 M |
-$59.87 M |
-$42.14 M |
-$37.27 M |
| EBITDA Ratio |
-2.76
|
-1.14
|
-1.51
|
-1.79
|
-3.6
|
-20.01
|
-29.27
|
-31.98
|
-22.8
|
-21.73
|
| Operating Income Ratio |
-2.7
|
-1.41
|
-1.53
|
-1.79
|
-3.61
|
-20.3
|
-29.71
|
-32.2
|
-22.96
|
-21.83
|
| Total Other Income/Expenses Net |
-$21.73 M
|
$1.65 M
|
$7.62 M
|
$71.48 M
|
-$92.79 M
|
-$570,000.00
|
-$860,000.00
|
-$1.46 M
|
-$1.38 M
|
-$1.55 M
|
| Income Before Tax |
-$193.51 M
|
-$80.74 M
|
-$71.04 M
|
-$6.55 M
|
-$155.64 M
|
-$86.37 M
|
-$59.98 M
|
-$63.39 M
|
-$44.70 M
|
-$39.75 M
|
| Income Before Tax Ratio |
-3.04
|
-1.38
|
-1.38
|
-0.15
|
-8.94
|
-20.43
|
-30.14
|
-32.96
|
-23.69
|
-22.71
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$7.62 M
|
$4.25 M
|
$4.00 M
|
$3.56 M
|
-$2.29 M
|
$272,000.00
|
$798,000.00
|
$977,000.00
|
| Net Income |
-$193.51 M
|
-$80.74 M
|
-$63.42 M
|
-$10.80 M
|
-$159.63 M
|
-$89.94 M
|
-$57.69 M
|
-$63.39 M
|
-$44.70 M
|
-$39.75 M
|
| Net Income Ratio |
-3.04
|
-1.38
|
-1.23
|
-0.25
|
-9.17
|
-21.28
|
-28.99
|
-32.96
|
-23.69
|
-22.71
|
| EPS |
-1.22 |
-1.09 |
-0.83 |
-0.14 |
-2.63 |
-1.99 |
-1.51 |
-2.2 |
-1.8 |
-1.71 |
| EPS Diluted |
-1.22 |
-1.02 |
-0.83 |
-0.13 |
-2.63 |
-1.99 |
-1.51 |
-2.2 |
-1.8 |
-1.71 |
| Weighted Average Shares Out |
$158.27 M
|
$79.83 M
|
$76.88 M
|
$76.39 M
|
$60.75 M
|
$45.27 M
|
$38.12 M
|
$28.82 M
|
$24.82 M
|
$23.24 M
|
| Weighted Average Shares Out Diluted |
$158.27 M
|
$85.60 M
|
$76.88 M
|
$82.16 M
|
$60.75 M
|
$45.27 M
|
$38.12 M
|
$28.82 M
|
$24.82 M
|
$23.24 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
